Reply to Padmanabhan and Dixit: Hepatitis C Virus Entry Inhibitors for Optimally Boosting Direct-acting Antiviral-based Treatments

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2017 May 18

PMID 28512226

Citations 4

Authors

Hirofumi Ohashi

Yoshiki Koizumi

Kento Fukano

Takaji Wakita

Alan S Perelson

Shingo Iwami

Koichi Watashi

Affiliations

Soon will be listed here.

Citing Articles

Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs.

Raja R, Pareek A, Newar K, Dixit N PLoS Pathog. 2019; 15(4):e1007701.

PMID: 30934020 PMC: 6459561. DOI: 10.1371/journal.ppat.1007701.

Building a mechanistic mathematical model of hepatitis C virus entry.

Kalemera M, Mincheva D, Grove J, Illingworth C PLoS Comput Biol. 2019; 15(3):e1006905.

PMID: 30883541 PMC: 6445459. DOI: 10.1371/journal.pcbi.1006905.

Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era.

Raja R, Baral S, Dixit N Immunol Rev. 2018; 285(1):55-71.

PMID: 30129199 PMC: 6614028. DOI: 10.1111/imr.12689.

Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection.

Venugopal V, Padmanabhan P, Raja R, Dixit N PLoS Comput Biol. 2018; 14(7):e1006335.

PMID: 30001324 PMC: 6057683. DOI: 10.1371/journal.pcbi.1006335.

References

Nieland T, Penman M, Dori L, Krieger M, Kirchhausen T . Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Proc Natl Acad Sci U S A. 2002; 99(24):15422-7. PMC: 137732. DOI: 10.1073/pnas.222421399. View

Koizumi Y, Ohashi H, Nakajima S, Tanaka Y, Wakita T, Perelson A . Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Proc Natl Acad Sci U S A. 2017; 114(8):1922-1927. PMC: 5338374. DOI: 10.1073/pnas.1610197114. View

Chou T . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58(3):621-81. DOI: 10.1124/pr.58.3.10. View

de Jong Y, Dorner M, Mommersteeg M, Xiao J, Balazs A, Robbins J . Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med. 2014; 6(254):254ra129. PMC: 4312107. DOI: 10.1126/scitranslmed.3009512. View

Morin T, Broering T, Leav B, Blair B, Rowley K, Boucher E . Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog. 2012; 8(8):e1002895. PMC: 3431327. DOI: 10.1371/journal.ppat.1002895. View

Shen L, Peterson S, Sedaghat A, McMahon M, Callender M, Zhang H . Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med. 2008; 14(7):762-6. PMC: 2743464. DOI: 10.1038/nm1777. View

Mailly L, Xiao F, Lupberger J, Wilson G, Aubert P, Duong F . Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol. 2015; 33(5):549-554. PMC: 4430301. DOI: 10.1038/nbt.3179. View

Padmanabhan P, Dixit N . Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations. Proc Natl Acad Sci U S A. 2017; 114(23):E4524-E4526. PMC: 5468610. DOI: 10.1073/pnas.1704531114. View

Law M, Maruyama T, Lewis J, Giang E, Tarr A, Stamataki Z . Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med. 2007; 14(1):25-7. DOI: 10.1038/nm1698. View

10.

Xiao F, Fofana I, Thumann C, Mailly L, Alles R, Robinet E . Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut. 2014; 64(3):483-94. PMC: 4345833. DOI: 10.1136/gutjnl-2013-306155. View

11.

Lupberger J, Zeisel M, Xiao F, Thumann C, Fofana I, Zona L . EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med. 2011; 17(5):589-95. PMC: 3938446. DOI: 10.1038/nm.2341. View